NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
kenneth o byrne
Queensland University of Technology - Brisbane / Australia
Natural Sciences / Molecular Biology & Genetics
AD Scientific Index ID: 125300
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
kenneth o byrne's MOST POPULAR ARTICLES
1-)
Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancerM Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...N engl J med 375, 1823-1833, 201676272016
2-)
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung CancerJC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, ...New England journal of medicine 378 (2), 113-125, 201839522018
3-)
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancerSJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...New England Journal of Medicine 377 (20), 1919-1929, 201740482017
4-)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung CancerAT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ...New England Journal of Medicine 368 (25), 2385-2394, 201341012013
5-)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsLV Sequist, JCH Yang, N Yamamoto, K O\'Byrne, V Hirsh, T Mok, ...Journal of clinical oncology 31 (27), 3327-3334, 201337992013
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept